Citations

Clear

207 citation(s) found for "Lu, Henri".

Long term treatment with tafamidis in ATTR-CM: 7.5 year outcomes from the phase 3 open label long-term extension study
Damy, T, Garcia-Pavia, P, Witteles, R, Grogan, M, Marino, V, Wang, R, Sperry, B W, Damy, Thibaud , Garcia-Pavia, Pablo , Grogan, M, Sperry, Brett W

Mayo Clinic

European Journal of Heart Failure | June 29, 2026 | Volume: 28 | Issue: Supplement_2 | Pages: No page available

10.1093/ejhf/xuag193.520 Get It

Abstract Background Tafamidis is a near-complete transthyretin kinetic stabiliser for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM). It is administered orally, once daily, and has demonstrated a statistically significant reduction in mortality at 30 months vs placebo. Purpose Report findings from patients who received up to 7.5 years treatment with tafamidis in the phase 3 trial and its long-term extension (LTE) study. Methods In ATTR-ACT, patients were randomised (2:1:2) to blinded tafamidis meglumine 80 mg, 20 mg, or placebo for 30 months. Patients continued their blinded tafamidis dose into the up to 60-month LTE study, until commercial prescription availability, or study termination. Those who received placebo in ATTR-ACT were randomized (2:1) to blinded tafamidis meglumine 80 mg or 20 mg in the LTE study. All patients were subsequently switched to open label tafamidis free acid 61 mg (bioequivalent to meglumine 80 mg). Outcomes were assessed over the entire 90-month follow-up. Results Of the 264 patients randomised to tafamidis in ATTR-ACT, 173 completed the trial and 170 continued to receive tafamidis the LTE study (Taf/Taf group). Of 177 patients randomised to placebo in ATTR-ACT, 85 completed the trial and 82 initiated tafamidis in the LTE study (Pbo/Taf group). Over a median follow-up of 54.2 months in the Taf/Taf group and 30.5 months in the Pbo/Taf group, incidence of all-cause mortality (ACM) was 54.5% and 71.2%. Median time to ACM was 47.5 and 30.3 months, resulting in a hazard ratio of 0.62 (95% CI: 0.49-0.79; P=0.0001; Figure). Incidence of cardiovascular-related mortality (CVM) was 42.0% and 57.1% in the Taf/Taf and Pbo/Taf groups. Median time to CVM was 47.6 and 30.3 months, resulting in a hazard ratio of 0.61 (0.47-0.81; P=0.0005). The total annual rate of all-cause hospitalisation in the LTE study was 0.69 in the Taf/Taf group and 1.14 in the Pbo/Taf group, and the total annual rate of cardiovascular-related hospitalisation was 0.36 and 0.63. Among patients remaining at each LTE study visit and with available data, improvement in New York Heart Association functional classification was more commonly seen in the Taf/Taf vs Pbo/Taf group. Mean observed reduction from baseline in Kansas City Cardiomyopathy Questionnaire Overall Summary score was significantly smaller in the Taf/Taf vs Pbo/Taf group at most LTE study visits. Treatment-related adverse events occurred in 11.2% of the Taf/Taf and 23.2% of the Pbo/Taf groups during the LTE study and were consistent with the known safety profile of tafamidis. Conclusions With up to 7.5 years of follow-up data, this analysis of ATTR-ACT trial and its LTE study is the longest reported to date for an ATTR-CM population treated with disease-modifying therapy. Findings demonstrate better long-term outcomes including survival, hospitalisation rates, quality of life, and heart failure symptoms with long-term tafamidis treatment. For image description, please refer to the figure legend and surrounding text.
Computed tomography ‐derived extracellular volume fraction is associated with high‐grade recurrence in non‐muscle‐invasive bladder cancer treated with intravesical gemcitabine and docetaxel
Chakra, Mohamad Abou, Alsamarah, Issa, Hougen, Helen Y., Brown, James A. , Marchetti, Kathryn , Henning, Grant , Duquesne, Igor , Buhaş, Bogdan Adrian , O’Donnell, Michael A. , Hougen, Helen Y. , Duquesne, Igor , Buhas, Bogdan Adrian , O'Donnell, Michael A , Henning, Grant M , Chakra, Mohamad Abou , Zakharia, Yousef , Myers, Amanda A. , Mott, Sarah L.

Mayo Clinic

BJU International | May 28, 2026 | Volume: 138 | Issue: 2 | Pages: 306-314

10.1111/bju.70319 | PMID 42206900 Get It

Objectives To evaluate whether extracellular volume (ECV) fraction derived from contrast‐enhanced computed tomography (CT) is associated with recurrence risk in patients with treatment‐naïve high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC) receiving intravesical gemcitabine/docetaxel (Gem/Doce) therapy. Patients and Methods This retrospective cohort study, conducted at a tertiary referral centre, included 103 patients with HR‐NMIBC treated with intravesical Gem/Doce between 2012 and 2024. All patients underwent pre‐resection contrast‐enhanced CT with an equilibrium phase (~3 min post‐injection). Tumour ECV fraction (%) was calculated using the formula: ECV = (ΔHUtumour/ΔHUaorta) × (1 − haematocrit) × 100, where Δ Hounsfield units (HU) represents the change in attenuation between non‐contrast and equilibrium phases. Regions of interest were manually placed in the tumour and abdominal aorta, and haematocrit values obtained within ±10 days were used. Associations between clinical variables, ECV, and recurrence were evaluated using Cox proportional hazards models, with discrimination assessed by Uno's C‐statistic. Results The median (interquartile range) follow‐up was 17 (10–25) months. High‐grade recurrence‐free survival (HG‐RFS) was 76% at 12 months and 69% at 24 months. CT‐derived ECV was the only variable significantly associated with HG‐RFS (hazard ratio 1.05, 95% confidence interval 1.03–1.08), demonstrating strong discrimination (C‐statistic, 0.81; P < 0.01). A 15% threshold offered the best sensitivity–specificity trade‐off (~70% each) for predicting HG‐RFS at 12 and 24 months. Patients with ECV ≤15% had markedly better HG‐RFS than those with ECV >15% at 24 months (88% vs 41%). Conclusions The CT‐derived ECV is a practical, first‐of‐its‐kind imaging biomarker associated with recurrence risk and useful for risk stratification in patients with HR‐NMIBC treated with intravesical Gem/Doce, a regimen increasingly used in the setting of global Bacillus Calmette‐Guérin shortages and intolerance. ECV can be rapidly quantified from routine contrast‐enhanced CT using standard picture archiving and communication system (PACS) tools, without additional imaging or proprietary software, making it a feasible metric for integration into risk‐adapted management pending large‐scale validation with extended follow‐up.
Temporal relationship between hematoma resolution and functional recovery after middle meningeal artery embolization for chronic subdural hematoma
DeMessie, Bluyé , Essibayi, Muhammed Amir, Karandish, Alireza, Park, Jaewoo , Haranhalli, Neil, Baker, Amanda, Zampolin, R, Brook, A, Lee, S, Adeeb, Nimer, Li, Yan-Lin, Ortega, Diego Alejandro, Cancelliere, N, Diestro, Jose Danilo, Carnevale, Joseph A., Schreiber, Craig , Abecassis, Zachary, Raub, Spencer, Sioutas, Georgios S. , Kvint, Svetlana , Falzon, Andrew, Cantrell, Vance, Holliday, Brian, Maleknia, Pedram D., Cruz-Criollo, Leonardo, Schimmel, Samantha, Musmar, Basel, Alexander, Matthew D. , Zermeno, Jorge Rios, Koul, Prateeka , Aljuboori, Ahmed , Vollherbst, D, Cooper, J , Ogilvy, Christopher S., Al-Mufti, Fawaz, Möhlenbruch, Markus A., Scarcia, Luca, Schirmer, Clemens M., Huynh, Thien, Settecase, Fabio , Tjoumakaris, Stavropoula, Jabbour, Pascal, Vakharia, Kunal, Zanaty, Mario, Ortega-Gutierrez, Santiago, Jones, J, Nasser, Hussein H., Sundararajan, Sri Hari , Mosimann, Pascal J., Nossek, Erez , Raz, Eytan, Kasab, S Al, Spiotta, Alejandro M., Michelozzi, Caterina , Saraceno, Davide , Srinivasan, Visish M., Burkhardt, Jan-Karl, Santini, Pietro Mario, Levitt, Michael R., Lanzino, Giuseppe, Brinjikji, Waleed, Knopman, Jared, Kass-Hout, T, Spears, Julian, Marotta, Thomas, Pereira, Vitor Mendes, Fuschi, Maurizio , Dmytriw, Adam A., Altschul, David J., _, _, Kostynskyy, Alex , Goren, Oded , Oliver, Jeffrey Daniel, Milnerowicz, Małgorzata , Papaxanthos, Jean , Eker, Omer, Barreau, Xavier, Courret, Thomas , Berge, Jerome, Engelhardt, Julien , Diestro, Jose Danilo Bengzon , Li, Yan-Lin , Rios Zermeno, Jorge , Diestro, Jose Danilo B , Li, Yan-Lin , Essibayi, Muhammed Amir , Salim, Hamza , Karandish, Alireza , Khatri, Deepak , Haranhalli, Neil , Zampolin, Richard L. , Adeeb, Nimer , Simonato, Davide , Ortega-Moreno, Diego Alejandro , Cancelliere, Nicole M , Carnevale, Joseph Anthony , Orscelik, Atakan , Abecassis, Zachary A. , Raub, Spencer , Salsano, Giancarlo , Kasem, Rahim Abo , Falzon, Andrew , Abaricia, Jefferson O. , Maleknia, Pedram Daniel , Cruz‐Criollo, Leonardo , Schimmel, Samantha J. , Musmar, Basel , Gajski, Domagoj, Alwakaa, Omar , Ogilvy, Christopher S. , Al‐Mufti, Fawaz , Kalousek, Vladimir , Möhlenbruch, Markus , Scarcia, Luca , Schirmer, Clemens M. , Huynh, Thien , Tawk, Rabih G. , Tjoumakaris, Stavropoula , Jabbour, Pascal , Zanaty, Mario , Ortega-Gutierrez, Santiago , Jones, Jesse , Colasurdo, Marco , Nasser, Hussein, Mosimann, Pascal J , Raz, Eytan , Spiotta, Alejandro M , Castellan, Lucio , Sette, Bruno Del , Panni, Pietro , Srinivasan, Visish M. , Burkhardt, Jan‐Karl , Marnat, Gaultier , Levitt, Michael R. , Lanzino, Giuseppe , Brinjikji, Waleed , Knopman, Jared , Kass‐Hout, Tareq , Spears, Julian , Dmytriw, Adam A. , Altschul, David , Galecio‐Castillo, Milagros , Cespedes, Jorge , Oliver, Jeffrey , Eker, Omer , Barreau, Xavier , Berge, Jérôme , Jecko, Vincent

Mayo Clinic

Journal of Neurosurgery | May 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-12

10.3171/2025.12.jns251884 | PMID 42172679 Get It

OBJECTIVE The objective was to evaluate the trajectories of hematoma resolution and functional improvement after middle meningeal artery embolization (MMAE) for chronic subdural hematoma (cSDH), model the temporal pattern of cSDH resolution, and identify factors associated with favorable outcomes. METHODS This real-world multicenter retrospective study included cSDH patients treated with MMAE at 24 centers between 2019 and 2024. Hematoma thickness was measured at baseline and at follow-up intervals (1–4 weeks, 1–3 months, 3–6 months, 6–12 months, and > 12 months after embolization). Resolution patterns were modeled using exponential decay functions. Modified Rankin Scale (mRS) scores assessed functional outcomes. Good functional outcome was defined as mRS score ≤ 2. Resolution patterns were modeled using exponential decay functions to estimate time to 50% and 80% reduction. Patients were categorized as complete resolution (≥ 99%) or by quartile of the remaining distribution (substantial [73%–98%], moderate [53%–73%], partial [27%–53%], minimal [< 27%]). The primary outcome was good functional status (mRS score ≤ 2). RESULTS The authors analyzed a total of 1781 patients with 2295 cSDHs who underwent MMAE. The mean ± SD age was 72.8 ± 12.4 years and 68.1% of patients were male. The initial mean hematoma thickness was 15.31 ± 6.53 mm, decreasing to 5.24 ± 5.91 mm at final follow-up (mean reduction 64.3% ± 42.1%). Resolution followed an exponential decay pattern, with an estimated time to 50% reduction of 1.8 months and to 80% reduction of 8.9 months. Complete resolution occurred in 1031 of 2224 patients (46.4%) with complete follow-up. The median (IQR) mRS score improved from 1 (0–3) at baseline to 0 (0–2) at > 12 months. Good functional outcomes were more common in patients with complete versus minimal resolution (68.9% vs 35.0%, p < 0.001). Achieving ≥ 73% resolution within 90 days was associated with better outcomes (good outcome in 76.9% of those with ≥ 73% resolution vs 67.3% in those without, p < 0.001). Neurological deterioration was the strongest predictor of lack of good outcome (23.7% in patients with neurological deterioration vs 82.4% without, p < 0.001). CONCLUSIONS After MMAE for cSDH, reduction in hematoma thickness follows a predictable exponential decay pattern. Greater extent (≥ 80%) and faster timing (within 90 days) of resolution are valuable prognostic indicators. Functional outcomes improve progressively through 6–12 months after the procedure. The relationship between resolution extent and functional outcomes provides quantitative benchmarks for evaluating treatment response.
Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry
Castrejón-Castrejón, Sergio , Heeger, Christian-Hendrik H., Veltmann, Christian, Schaack, David , Nies, Moritz , Gunawardene, Melanie , Steven, Daniel , Tscholl, Verena , Roten, Laurent, Sommer, Philipp, Spartalis, Michael , Seitz, Julien , Kistler, Peter M, Chen, Minglong, Wang, Q , Munoz, Freddy Del-Carpio, Wijnmaalen, Adrianus P. , Moreno, Javier , Albarrán-Rincón, Ramón, Sanders, Prashanthan, Blessberger, Hermann , Laredo, Mikaël, Krahnefeld, Olaf , Pernat, Andrej , Aro, Aapo L. , Martinez, Eduardo Castellanos, Scazzuso, Fernando , Neven, Kars , Yorgun, Hikmet , Natale, Andrea, Joung, Boyoung, Wichterle, Dan, Cay, Serkan, Andorin, Antoine , Kato, Hiroyuki, Carnero, Guillermo, Maciąg, Aleksander, Garkina, S. V. , Deharo, Jean-Claude, Sadek, Mouhannad M, Iwasaki, Yu-ki, Beiert, Thomas , Choi, Eue-Keun, Kojic, D, Bergau, Leonard, Lellouche, N, Cortés, Luis Arabia, Camargo, Juan Manuel, Inaba, Osamu, Szegedi, Nándor , Piccini, Jonathan P., Marijon, Eloi, Mazurek, M , Sandgaard, Niels C F, Francke, Alexander , Schumacher, Burghard, Sánchez, Christian David Adams, Garcia-Izquierdo, E G I Eusebio, Guerra, Jose M., Aboulmaaty, Mervat , Jansen, Henning , Metzner, Andreas , García, Cecilia Zapata , Chun, J. K. R., Merino, José L, investigators, The EMBOL-AF, Benkouar, Riad, Abello, Maurício, Aguinaga, Luis, Correa, Mariel Alvarez , Estrada, Alejandro , Figueroa, Jorge, López, Leonardo Guido, Mondragón, Ignacio, Hovakimyan, Tatevik , Kalman, Jonathan, Maisels, Leonid, Kistler, Bruno Scardamaglia, Crowley, Rose , Steinwender, Clemens , Kousta, Mary, Scherr, Daniel, Goelly, Katharina Ingrid, Rocca, Domenico Giovanni Della, Potter, Tom J R De, Boškić, Mario, D’Avila, Andre, Guimarães, Henrique Cerqueira , Slater, Charles , Saad, Eduardo, Marchov, D. , Ayala-Paredes, Félix Alejandro, Glover, Benedict, Khaykin, Yaariv, Silva, Armando Pérez, Salvatici, Luis Quiñiñir, Li, Mingfang, Yao, Yan, Zhou, Li , Yi, Fu, Zeng, Rui, Molano, Luis Fernando Pava, Velasco, Víctor Manuel, Ramírez, Santiago Giraldo , Morales, Luis Carlos Saenz, Radeljić, Vjekoslav , Larsen, Jacob Moesgaard, Jacobsen, Peter Karl, Liñero, Mikel, Patete, Manuel , Hallon, Luis, Rivadeneira, José Llorente, Moustafa, Ahmed, Botros, Michael Sobhy, Minois, Damien , Anselme, Frédéric, Bakouboula, Babé, Schaaf, Mathieu , Boveda, Serge, Richard-Vitton, Robin, Détis, Nicolas, Fauchier, Laurent, Pierre, Bertrand , García, Rodrigue, Degand, Bruno , Salaün, Alexandre, Gandjbakhch, Estelle, Martins, Raphael, Maury, Philippe, Milhem, Antoine , Arnaout, Alain Al, Pavin, Dominique , Piot, Olivier, Ballatore, Andrea, Zhao, Alexandre , Papiashvili, Giorgi , Rekvava, Roin , Avranas, Konstantinos, Eckardt, Lars, Forkmann, Mathias , Busch, Sonia, Harloff, Tim, Halbfass, Philipp, Hilss, Karen Anja, Kaufmann, Jan , Thilotray, Christian, Poley, Phillip, Küchler, Mirco , Tilz, Roland Richard, Maslova, Vera , Lian, Evgeny, Füting, Anna , Letsas, Konstantinos P., Papakonstatinou, Panteleimon, Tzeis, Stylianos, Geller, Laszlo, Narasimhan, Calambur, Koduri, Venkata Krishna Chaitanya, Ghosh, Anindya, Lubis, Anggia Chairuddin , Emkanjoo, Zahra , Eslami, Masoud, Conti, Sergio, Perrotta, Laura , Pieragnoli, Paolo , Poggi, Sara, Ruggiero, Donatella, Aurino, L, Russo, Vicenzo, Hashiguchi, Naotaka , SHIMIZU, Wataru, Yodogawa, Kenji , Suga, Kazumasa , Yamaguchi, Takanori, Bakytzhanuly, Abay, Dussekeyeva, Gulnoza, Dehkhanova, Shakhnoza, Kupics, Kaspars, Jubele, Kristine, Refaat, Marwan M, Ghazawi, Alaaeddine El, Sammut, Mark A, Márquez-Murillo, Manlio F., Rogel-Martínez, Ulises, Nolasco, Karla Bozada, Khurelbaatar, Mungun-Ulzii, Dagdan, Batnaran, Kooijman, Edwin, Martin, Andrew, Kiliszek, Marek, Kulakowski, Piotr, Żuk, Anna , Lebreiro, Ana , Diaz, Nuno Cortez, Cozma, Dragos, Grecu, Mihaela, Rudzik, Roxana, Sipos, Sergiu, Vatasescu, Radu, Lebedev, Dmitry, Lee, So-Ryoung, Kim, Daehoon, Luque, Miguel Amores , Arenal, Ángel, Alonso, Pablo Ávila , Sanchez, Antonio Berruezo, Cabanas-Grandío, Pilar, Cózar-León, Rocío, Díaz-Infante, Ernesto, Fernández-Armenta, Juan, Fernández-Gómez, Juan Manuel, Jaén, Eusebio García-Izquierdo , García-Olea, Alain, Gaztañaga, Larraitz , Guasch, E, Criado, José Luis Ibáñez, Garrido, Beatriz Jáuregui, Sierra, Cristina Martin, Osca, Joaquin, Castellano, Nicasio Pérez, Ocete, Blanca Quesada, Rivas-Gándara, Nuria, Rubio-Campal, José Manuel, Brotons, J.A. Sánchez, Sánchez-Somonte, Paula, Segura, Jose Maria, Segura-Villalobos, Federico, Hernández, Pablo Ruiz, Soria, Laura Valverde , Fengsrud, Espen, Reichlin, Tobias, Krisai, Philipp, Tramèr, Lucas, Ngarmukos, Tachapong , Trines, Serge A., Mulder, Bart A. , İhtisas, Yüksek, Yilancioğlu, Yiğit, Şahin, Durmuş Yıldıray , Yalin, Kivanc, Yalman, Hakan , Aytemir, Kudret, Martin, Claire A , Zeriouh, Sarah , Abbas, Mohamed Magdi, Chamoun, Nadia , Bsoul, Mayana, Mohanty, Sanghamitra, Uzokov, Jamol, Benchetrit, Chamia, Choi, Jong‐Il , Joung, Boyoung , Roten, Laurent , Del-Carpio Munoz, Freddy , Sanders, Prashanthan , Sticherling, Christian , Joung, Boyoung , Wichterle, Dan , Cay, Serkan , Kato, Hiroyuki , Deharo, Jean Claude , Choi, Eue-Keun , Bergau, Leonard , Lellouche, Nicolas , Marijon, Eloi , Ramos Jiménez, Javier , Metzner, Andreas , Pürerfellner, Helmut , Merino, Jose L , Heeger, Christian-Hendrik H. , Veltmann, Christian , Sommer, Philipp , Kistler, Peter M. , Chen, Ming-Long , Munoz, Freddy Del‐Carpio , Albarrán‐Rincón, Ramón , Sanders, Prashanthan , Laredo, Mikael , Guénancia, Charles , Natale, Andrea , Almorad, Alexandre , Ruwald, Martin H , Carnero, Guillermo A. , Deharo, Jean‐Claude , Sadek, Mouhannad M. , Iwasaki, Yu‐ki , Choi, Eue‐Keun , Kojić, Dejan , Sousa, João de , Bergau, Leonard , Inaba, Osamu , Piccini, Jonathan P. , Marijon, Éloi , Sandgaard, Niels C. F. , Stiles, Martin K. , García‐Izquierdo, Eusebio, Ares, Gerardo Ruiz , Aguinaga, Luis, Munawar, Dian Andina , Puvrez, Alexis , Gölly, Katharina Ingrid , Rocca, Domenico G. Della , Begić, Edin , d'Avila, Andre, Guimaraes, Henrique, Saad, Eduardo , Dzhinsov, Krasimir R. , TRAYKOV, VASSIL BORISLAVOV , Paredes, Felix Ayala , Glover, Benedict , Macle, Laurent , Khaykin, Yaariv , Pérez-Silva, Armando , Díaz, Juan Carlos , Giraldo-Ramírez, Santiago, Morales, Luis C. Sàenz, Đula, Kristijan , Peichl, Petr , Larsen, Jacob Moesgaard , Jacobsen, Peter Karl , Hallon, Luis A., Rivadeneira, José Elizardo Llorente , Botros, Michael, Anselme, Frédéric , Chaumont, Corentin , Bakouboula, Babé , Bovéda, Serge , Richard-Vitton, Robin , Boulé, Stéphane , Fauchier, Laurent , Garcia, Rodrigue , Salaun, Alexandre, Gandjbakhch, Estelle , Martins, Raphaël P. , Maury, Philippe , Beneyto, Maxime M , Piot, Olivier , Ballatore, Andrea , Asbach, Stefan , Avranas, Konstantinos, Didenko, Maxim , Eckardt, Lars , Harloff, Tim , Halbfaß, Philipp , Tilz, Roland Richard , Lian, Evgeny, Sohns, Christian , Lüker, Jakob , Zabel, Markus , Letsas, Κonstantinos P. , Leventopoulos, Georgios , Tzeis, Stylianos , Kupó, Péter , Geller, Laszlo A. , Narasimhan, Calambur, Pandurangi, Ulhas M. , Ghosh, Anindya , Haim, Moti , Konstantino, Yuval , Barletta, Valentina , Cipolletta, Laura , Conti, Sergio , Sgarito, Giuseppe A. , Poggi, Sara , Ruggiero, Donatella , Ejima, Koichiro , Shimizu, Wataru, Kato, Hiroyuki, Abdrakhmanov, Ayan Suleimenovich , Bakytzhanuly, A, Kupics, Kaspars , Jubele, Kristīne , Refaat, Marwan M., Ghazawi, Alaaeddine El , Sammut, Mark Adrian , Rojel-Martínez, Ulises, Bozada-Nolasco, Karla I., Denysiuk, Piotr , Farkowski, Michał M. , Futyma, Piotr , Zarębski, Łukasz , Kiliszek, Marek , Kulakowski, Piotr , Lenarczyk, Radosław , Miśkowiec, Dawid Łukasz , Sousa, Pedro , Grecu, Mihaela, Arenal, Ángel , Cabanas‐Grandío, Pilar , León, Rocío Cózar , Dı́az-Infante, Ernesto , Fernandez-Armenta, Juan, Olea, Alain García, Guasch, Eduard , Ibáñez, José Luis , Garrido, Beatriz Jáuregui, Osca, Joaquín , Rivas‐Gándara, Nuria , Campal, J M Rubio, Sánchez-Somonte, Paula , Segura, José María, Fengsrud, Espen , Bergonti, Marco , Reichlin, Tobias , Krisai, Philipp , Tramèr, Lucas , Trines, Serge A.I.P. , Özkan, Eyüp , Özcan, Emin Evren , Yılancıoğlu, Yiğit, Yalın, Kıvanç , Aytemir, Kudret , Abbas, Mohamed Magdy, Akoum, Nazem , Bsoul, Mayana , Mohanty, Sanghamitra

Mayo Clinic

European Heart Journal | March 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurheartj/ehag217 | PMID 41914181 Get It

Abstract Background and Aims Stroke and systemic embolism are recognized but poorly characterized complications of atrial fibrillation (AF) and left atrial flutter (AFL) catheter ablation. Their incidence, outcomes, and procedural associations remain insufficiently defined. Methods Retrospective global registry was initiated by the European Heart Rhythm Association Scientific Committee. A secure database captured data from ablation centres worldwide on general AF and left AFL ablation activity, as well as detailed information on patients with symptomatic embolic events between 2017 and 2024. Results Overall, 204 centres reported 335 743 ablation procedures and 550 embolic events (incidence 0.16%). Centre-level rate ranged from 0% to 3.1%. Most events were cerebral (94%), followed by peripheral (5%), and combined (1%). Coronary air embolism accounted for 62% of all peripheral events. Intraprocedural events occurred in 93 patients (17%), within 72 h in 357 (78%) and beyond 72 h in 100 (22%); 128 cases (23%) were diagnosed after hospital discharge. Nonparoxysmal AF (0.23% vs 0.15%; P &lt; .001), centre experience, and ablation energy source (radiofrequency, 0.16%; cryoballoon, 0.16%; pulsed field ablation, 0.25%; laserballoon, 0.88%; P &lt; .001) were associated with embolic risk. Median NIHSS score after stroke was 4 (interquartile range, 2–9). Three-month follow-up was available for 518 patients with embolism (95%): 181 (35%) had sequelae and 16 (3%) died. Conclusions Symptomatic embolic events are infrequent but associated with significant morbidity and mortality. Most events occur early, though a substantial proportion arise later. Higher event rates were observed with laser and possibly with pulsed field ablation. A greater centre experience was associated with a lower embolism incidence.
CLOCK is an Epigenetic Integrator of Circadian Rhythm and T Cell Immunity
Khazaie, Khashayarsha , Eyvazi, Shirin , Osman, Abu, Singh, Mahendra Pal, Marlow, Cameron, Keshavarzian, Ali, Bishehzari, Faraz, Sobhani, Iradj, Matveyenko, A., Gounari, Fotini , Eyvazi, Shirin , Osman, Abu, Saadalla, Abdulrahman , Keshavarzian, Ali , Sobhani, Iradj , Gounari, Fotini

Mayo Clinic

No container title available | March 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9107841/v1 | PMID 41928813 Get It

Abstract The circadian clock imposes a critical yet incompletely understood layer of regulation on adaptive immunity. T helper 17 (Th17) antimicrobial immune responses including expression of IL-17A by lamina propria CD4⁺ T cells, exhibit diurnal variation and are sensitive to circadian disruption. While the core circadian regulators CLOCK and BMAL1 canonically function as a heterodimer to drive rhythmic gene expression, emerging evidence suggests they may have distinct regulatory roles. Here we integrated ChIP-seq, ATAC-seq, and RNA-seq analyses in naïve CD4⁺ T cells to reveal that the CLOCK-BMAL1 complex controls circadian and metabolic programs through promoter binding, whereas exclusive CLOCK binding at promoters, together with CLOCK-BMAL1 binding at enhancers, regulates immune-associated genes. Using the mutant CLOCKΔ19, which lacks the transactivation domain, we observed disrupted circadian transcription and globally reduced chromatin accessibility, alongside increased accessibility at Th17-associated loci that their altered temporal regulation. Functionally, ClockΔ19 produces β-catenin stabilization in T cells, pronounced expansion of RORγt⁺ CD4⁺ T cells and Treg cells, impaired Treg suppression of Th17 responses, heightened Th17 responses, and reduced IFN-γ production during viral infection. Collectively, these findings define BMAL1 dependent and independent CLOCK functions that program naïve CD4⁺ T cell fate, restrain Th17 differentiation, and preserve immune homeostasis.
Woven EndoBridge Device for Ruptured vs. Unruptured Aneurysms: Insights from the WorldWideWEB Study
Dugar, Franja, Essibayi, Muhammed Amir, Adeeb, N, Algin, Oktay, Ghozy, Sherief, Guenego, Adrien, Renieri, Leonardo, Saliou, G, Shotar, Eimad, Möhlenbruch, Markus, Kral, Michael , Chung, Charlotte, Salem, Mohamed M , Cancelliere, Nicole M., Diestro, Jose Danilo Bengzon, Foreman, Paul M. , Shaikh, Hamza, Župančić, Vedran , Waqas, M, Ayberk, Gıyas , Rabinov, James D. , Maingard, Julian , Schirmer, Clemens M., Piano, M, Michelozzi, Caterina , Starke, Robert M., Hassan, A. E., Ogilvie, Mark, Jones, Jesse, Brinjikji, Waleed , Psychogios, Marios, Nawka, Marie Teresa , Fiehler, Jens, Nguyen-Kim, Thi Dan Linh, Pukenas, Bryan , Burkhardt, J. David, Huynh, Thien, Martinez-Gutierrez, Juan Carlos, Sheth, S, Slawski, Diana , Lubicz, Boris , Puri, A, Raz, E, Griessenauer, Christoph J., Asadi, Hamed, Siddiqui, Adnan, Levy, Elad I, Haranhalli, Neil , Altschul, David, Ducruet, Andrew F. , Regenhardt, Robert W., Stapleton, Christopher J. , Kan, Peter , Lylyk, Pedro, Boddu, Srikanth, Knopman, Jared, Tjoumakaris, Stavropoula I., Cuellar-Saenz, Hugo H., Jabbour, Pascal M., Clarençon, Frédéric, Patankar, Tufail , Pereira, Vitor Mendes, Patel, Aman B., Almohammad, Mohammad, Kemmling, Andre, Dmytriw, Adam A., Diestro, Jose Danilo Bengzon , Diestro, Jose Danilo B , Dugar, Franja , Essibayi, Muhammed Amir , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Dibas, Mahmoud , Li, Yan-Lin, Algin, Oktay , Ghozy, Sherief , Lay, Sovann V. , Guenego, Adrien , Renieri, Leonardo , Carnevale, Joseph, Saliou, Guillaume , Mastorakos, Panagiotis , Shotar, Eimad , Möhlenbruch, Markus , Salem, Mohamed Raafet Ben, Lylyk, Iván , Cancelliere, Nicole M , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Ayberk, Gıyas , Arslan, Muhammet , Ergun, Onur, Maingard, Julian, Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna L., Starke, Robert M., Hassan, Ameer, Ogilvie, Mark , Jones, Jesse , Zaccagna, Fulvio , Grist, James T. , Psychogios, Marios‐Nikos , Fiehler, Jens , Nguyen‐Kim, Thi Dan Linh , Burkhardt, Jan‐Karl , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Tawk, Rabih G. , Pulli, Benjamin , Panni, Pietro , Puri, Ajit S., Pero, Guglielmo , Raz, Eytan , Griessenauer, Christoph J. , Asadi, Hamed , Siddiqui, Adnan H. , Levy, Elad I. , Altschul, David , Regenhardt, Robert W. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro, Knopman, Jared , Tjoumakaris, Stavropoula , Cuellar, Hugo , Jabbour, Pascal , Clarençon, Frédéric , Limbucci, Nicola , Patel, Aman B. , Almohammad, Mohammad , Kemmling, André , Scarcia, Luca , Dmytriw, Adam A. , Sporns, Peter Bernhard

Mayo Clinic

No container title available | March 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8939206/v1 Get It

Abstract Purpose Although the Woven EndoBridge (WEB) device is increasingly used for the treatment of wide-neck intracranial aneurysms, including in the acute rupture setting, comparative evidence assessing the impact of rupture status remains limited. This study compared angiographic, safety, and clinical outcomes between ruptured and unruptured intracranial aneurysms treated with WEB. Methods We conducted a retrospective analysis of prospectively collected data from the multicenter cohort registry WorldWideWEB, including consecutive adult patients with intracranial aneurysms treated with the WEB. Patients were stratified into groups of ruptured and unruptured aneurysms. Propensity score matching was used to balance baseline characteristics between both groups. Retreatment rate was the primary outcome. Secondary outcomes included mRS, safety events (thromboembolic complications) and angiographic outcomes (periprocedurally and last follow-up). Results Among 1,220 patients, 342 (28.0%) presented with ruptured aneurysms. There was no significant difference in the rate of thromboembolic complications between groups (11.8% vs 5.9%, p = 0.056). At follow-up, adequate occlusion was lower (82.2% vs 93.3%, p < 0.002) and functional outcomes were worse (mRS ≥2 in 34.1% vs 21.9%, p = 0.012) among patients with ruptured aneurysms. Periprocedural adequate occlusion (53.3% vs 53.8%, p>0.9) and retreatment rates (11.8% vs 7.1%, p = 0.14) did not differ between groups after matching. Conclusion Ruptured aneurysms demonstrated expected inferior follow-up functional and angiographic outcomes when compared with unruptured aneurysms, but no difference in retreatment rate and procedural safety. These findings support WEB as a safe and effective treatment option for appropriately selected ruptured intracranial aneurysms in routine clinical practice.
Integrative screening identifies functional variants and VNTRs underlying GWAS signals at the 5p15.33 multi-cancer susceptibility locus
O’Brien, Aidan , Kong, Hyunkyung, Patel, Harsh , Ho, Michelle , Patel, Minal, Zhong, Jun , Xu, Mai, Papenberg, Brenen W. , Connelly, Katelyn E. , Collins, Irene , Hennessey, Rebecca C. , Thakur, Rohit , Sowards, Hayley , Funderburk, Karen, Luong, Thong Minh, Florez-Vargas, Oscar , Myers, Timothy , Jermusyk, Ashley , Gorman, Bryan, Das, Sudipto, (PanScan/PanC4), The Pancreatic Cancer Cohort and Case-Control Consortia, Lan, Qing, Rothman, Nathaniel , McKay, James , Hung, R., Iles, Mark M. , Landi, Maria Teresa , Stolzenberg-Solomon, Rachael Z, Wolpin, Brian M. , Hassan, Manal M. , Antwi, Samuel O. , Lindström, Sara , Stern, Marc-Henri, Andrésson, Þorkell , Shi, Jianxin , Choi, Jiyeon, Brown, Kevin M, Rabe, Kari G. , Patel, Minal B , Hennessey, Rebecca , Luong, Thong , Jones, Kristine , Das, Sudipto , McKay, James , Hung, Rayjean J , Amos, Christopher I , Iles, Mark M , Koutros, Stella , Landi, Maria T , Law, Matthew H , Hassan, Manal M , Klein, Alison P , Orr, Nick , Chanock, Stephen Jacob , Lindstrom, Sara , Hoskins, Jason W , Shi, Jianxin , Prokunina-Olsson, Ludmila , Choi, Jiyeon , Brown, Kevin M , Amundadottir, Laufey , Chaffee, Kari G. , Antwi, Samuel O , Zhong, Jun , Luo, Wen , Lan, Qing , Rothman, Nathaniel , Amos, Christopher I. , Koutros, Stella , Law, Matthew H. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Orr, Nick , Hoskins, Jason W. , Stern, Marc‐Henri , Choi, Jiyeon , Ámundadóttir, Laufey T.

Mayo Clinic

No container title available | March 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.03.26347427 | PMID 41867231 Get It

Abstract Chromosome 5p15.33 harbors several independent association signals which demonstrate antagonistic pleiotropy across cancer types, with causal mechanisms largely unresolved. To identify functional variants and enhancer elements at this locus, we performed statistical fine-mapping followed by massively parallel reporter assays (MPRA) and proliferation based CRISPRi screens. This approach identified eight multi-cancer functional variants (MCFVs) across three GWAS signals. Targeting rs421629 (part of the CLPTM1L signal marked by rs465498) with CRISPRi revealed opposing effects on TERT expression in pancreatic versus lung cancer cells, consistent with the antagonistic pleiotropy observed for this signal. Furthermore, CRISPRi nominated an intronic CLPTM1L variable number tandem repeat (VNTR) as a potent enhancer. Long-read sequencing established VNTR polymorphisms as potential causal variants for the rs465498 signal. We showed that Hippo-pathway transcription factors mediate VNTR enhancer activity in lung and pancreatic cancer cells. Together, these findings indicate that cancer susceptibility at 5p15.33 may be mediated by both SNPs and VNTRs and provide an integrated framework for resolving complex pleiotropic loci.
The rise of transplant oncology in primary liver cancer and metastatic disease
Wassmer, Charles‐Henri , Gelli, Maximiliano , Wong, TM, Li, Zhihao, Zorigtbaatar, Anudari , Marino, Rebecca , Sierra, Laia Aceituno, Adam, René , Chan, Albert Chi Yan, Heimbach, Julie, Line, Pål Dag , Mazzaferro, Vincenzo , Sapisochin, G., Tabrizian, Parissa , Vogel, Arndt, Adam, René , Heimbach, Julie K. , Chan, Albert , Vogel, Arndt , Wong, Tiffany , Li, Zhihao , Marino, Rebecca , Wong, Tiffany C L , Li, Zhihao , Aceituno, L , Chan, Albert C Y , Heimbach, Julie K , Sapisochin, Gonzalo , Vogel, Arndt , Toso, Christian , Marino, Rebecca, Aceituno, Laia , Line, Pål‐Dag , Mazzaferro, Vincenzo , Sapisochín, Gonzalo , Toso, Christian

Mayo Clinic

Hepatology | February 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001723 | PMID 41746604 Get It

Background and Aims: Liver transplantation has evolved from a treatment restricted to patients with end-stage liver disease to a therapeutic option for selected patients with primary and metastatic liver malignancies. This review explores the rapidly expanding field of transplant oncology, highlighting its role in hepatocellular carcinoma, colorectal liver metastasis, neuroendocrine liver metastasis, and intrahepatic and perihilar cholangiocarcinoma. Emphasis is placed on strategies to broaden eligibility, optimize donor organ use, and improve oncologic outcomes. Approach and Results: We synthesized current evidence from clinical series, registries, and experimental protocols to evaluate patient selection criteria, outcomes, and peri-transplant management. Key topics include downstaging approaches to meet transplant criteria, such as locoregional therapies and systemic regimens, and their prognostic implications. Advances in donor utilization have been analyzed for their capacity to expand the graft pool. In addition, the review addresses the integration of oncologic principles into immunosuppression regimens, balancing graft protection with cancer control. Collectively, the reported studies demonstrate improved survival and reduced recurrence when stringent selection and multimodal therapy were applied. Conclusions: Transplant oncology reshapes the therapeutic landscape of liver malignancies, with growing evidence supporting liver transplantation in carefully selected patients beyond traditional indications. Optimized downstaging, innovative donor strategies, and tailored immunosuppression are pivotal for safe expansion. Continued collaboration between the transplant and oncology disciplines, along with prospective trials, is essential to further define standardized protocols and solidify transplantation as a cornerstone of multidisciplinary cancer care.
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis
Ammirati, Enrico, Palazzini, Matteo , Lehtonen, Jukka , Potena, Luciano , Mäyränpää, Mikko I. , Rågback, Johanna, Uribarri, Aitor , Thiele, H, Vidal‐Burdeus, María , Freund, Anne, Gustafsson, F., Tschöpe, C., Elsanhoury, Ahmed , Ihle, Joshua , Rudi, Wolf‐Stephan , Grabmaier, Ulrich , Merlo, Marco, Weislova, Ivana, Jellinghaus, Stefanie, Linke, A, Baldovini, Chiara , Adorisio, R, Kuchyňka, Petr, Palecek, T, Krejčí, Jan, Poloczková, Hana , Caterino, Anna Laura, Lovell, Jana , Macomb, Elaine P., Shih, Jeffrey, Hong, Kimberly N. , Ruschitzka, Frank, Cavallini, Claudio, Riccini, Clara, Kamal, Mohamed, Groh, Matthieu, Garascia, Andrea , Lala, Anuradha, Shimokawa, Hiroaki, Sionis, A, Schmidt, Matthieu, Grosu, Aurelia, Bollano, Entela , Turco, Annalisa , Crespo-Leiro, M., Couto-Mallón, David, Cannata, Antonio, Narducci, M L, Cicchitti, Vincenzo , Ianni, Umberto , L, De Luca, Frea, Simone, Schroeder, J. W., Arias, Aníbal , Emdin, Michele, Corda, Marco , Pasqualucci, Daniele , Greulich, Simon , Gawaz, M, Manuylova, Tatiana, Martinez-Selles, M, Pérez, Francisco José Hernández, Centellas, Alba Martín , Trankle, Cory R. , Halushka, Marc K., Abbate, Antonio, Basso, Cristina, Sinagra, Gianfranco, Veronese, Giacomo , Camici, PG, Adler, Eric D., Cooper, Leslie T., Gustafsson, Finn , Tschöpe, Carsten , Thiele, Hölger , Ammirati, Enrico , Potena, Luciano , Ammirati, Enrico , Foà, Alberto , Uribarri, Aitor , Thiele, Holger , Vidal-Burdeus, María , Freund, Anne , Gustafsson, Finn , Tschöpe, Carsten , Elsanhoury, Ahmed , Ihle, Joshua , Grabmaier, Ulrich , Merlo, Marco , Melenovský, Vojtěch , Weislova, Ivana , Linke, Axel , Baldovini, Chiara , Kuchynka, Petr , Krejčí, Jan , Gilotra, Nisha A , Hong, Kimberly , Rossi, Valentina A , Ruschitzka, Frank T. , Kamal, Mohamed , Huang, Florent , Groh, Matthieu , Gentile, Piero , Garascia, Andrea , Shimokawa, Hiroaki , Vandenbriele, Christophe , Sionis, Alessandro , Schmidt, Matthieu , Bollano, Entela , Crespo-Leiro, Maria Generosa , Cannatà, Antonio , Bromage, Daniel I , Narducci, Maria Lucia , Cicchitti, Vincenzo , Ianni, Umberto , De Luca, Leonardo , Mistrulli, Raffaella , Frea, Simone , Raineri, Claudia , Schroeder, Jan W , Arias, Anibal Martin , Emdin, Michele , Greulich, Simon , Gawaz, Meinrad , Martínez-Sellés, Manuel , Hernández Pérez, Francisco José , Dominguez, Fernando , D'Alessandris, Nicoletta , Trankle, Cory , Halushka, Marc K , Moroni, Francesco , Abbate, Antonio , Basso, Cristina , Sinagra, Gianfranco , Veronese, Giacomo , Camici, Paolo G , Adler, Eric D , Bernasconi, Davide P , Klingel, Karin , Cooper, Leslie T , Foà, Alberto , Vidal-Burdeus, María , Merlo, M, Melenovský, Vojtěch , Adorisio, Rachele , Paleček, Tomáš , Krejčí, Jan , Cavallini, Claudio , Riccini, Clara, Gentile, Piero , Lala, Anuradha , Shimokawa, Hiroaki , Vandenbriele, Christophe , Couto‐Mallón, David , Luca, Leonardo De , Frea, Simone , Corda, Marco , Domínguez, Fernándo , Gaillet, Antoine , Halushka, Marc K. , Abbate, Antonio , Basso, Cristina , Cooper, Leslie T.

Mayo Clinic

Circulation | February 6, 2026 | Volume: 153 | Issue: 9 | Pages: 634-652

10.1161/circulationaha.125.074797 | PMID 41645905 Get It

BACKGROUND: No large registries of patients with acute eosinophilic myocarditis (EM) are available. However, EM is perceived as a cardiac disease with high mortality, affecting mainly young and middle-aged adults according to small series and case reports. Awareness of the clinical presentation, associated systemic conditions, treatments, and outcomes of this uncommon condition is an unmet need. METHODS: In this international, multicenter, retrospective cohort study, 53 centers screened 193 patients with histologically proven acute EM between 1992 and 2023. After the exclusion of patients with insufficient data (n=10), symptoms lasting >30 days (n=19), or histological diagnosis not confirmed after review (n=8), 156 patients were included. RESULTS: Median age at presentation was 48 years (first to third quartile, 34–59 years) with male predominance (67.3%), and only 2 were pediatric cases (≤16 years of age; 1.3%). The main signs and symptoms at presentation were dyspnea (75.6%), fever (61.3%), and chest pain (53.2%). Unexpectedly, peripheral eosinophilia was reported in only 57.4% of cases, with a median cell count of 630 eosinophils/μL. The median left ventricular ejection fraction at presentation was 32% (first to third quartile, 25%–48%). The disorders most frequently associated with EM were eosinophilic granulomatosis with polyangiitis (22.4% of cases) and hypersensitivity forms (14.1%). Idiopathic/undefined forms accounted for 44.9% of cases, and miscellaneous causes accounted for 18.6%. In-hospital death or need for heart transplantation (HTx) occurred in 23 patients (14.7%; 22 deaths and 1 HTx), despite 43.6% being treated with temporary mechanical circulatory support and 92.9% being treated with immunosuppressive agents. Estimated rates of death or HTx at 1 and 3 years were 19.0% and 23.8%. Increased age, decreased left ventricular ejection fraction on admission, and no immunosuppressive therapy during hospitalization were independent predictors of death or HTx. A nonsignificant higher occurrence of deaths or HTx was observed in the hypersensitivity form (46.1%) compared with the eosinophilic granulomatosis with polyangiitis–associated form (13.1%) at 3 years ( P =0.15). CONCLUSIONS: Acute EM can often present without peripheral eosinophilia, and rates of in-hospital and midterm mortality or HTx are high. Endomyocardial biopsy is required to reach the final diagnosis of EM because relying on peripheral eosinophilia can lead to missing diagnosis. In-hospital immunosuppression is associated with HTx-free survival, although tailored immunosuppressive therapies are needed to improve outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06447935.
Tafamidis treatment significantly reduces the risk of recurrent cardiovascular-related hospitalisation in patients with early stage transthyretin amyloid cardiomyopathy
Damy, T, Witteles, R, Shah, S, Marino, Valentina , Wang, R, Grogan, M, Damy, Thibaud , Witteles, R, Cappelli, Francesco , Marino, V, Wang, R

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.1221 Get It

Abstract Background The clinical efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) was demonstrated during the phase 3, multinational, randomised, placebo-controlled Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT).(1) In ATTR-ACT, the risk of any cardiovascular (CV)-related hospitalisation was significantly reduced among patients who received tafamidis meglumine 80 mg (the approved dose) vs placebo (relative risk ratio 0.70 [95% CI 0.57, 0.85]; P=0.0005).(2) The benefit of tafamidis treatment was largest among patients with New York Heart Association (NYHA) class I/II vs III symptoms at baseline.(1,3,4) Purpose ATTR-CM is a progressive disease with a natural history that typically includes an increasing frequency of CV-related hospitalisation as the condition worsens. This post hoc analysis adds to current knowledge by evaluating the risk of recurrent (≥1) CV-related hospitalisation by baseline NYHA class in ATTR-ACT patients taking the approved dose of tafamidis or placebo. Methods Patients aged 18 to 90 years with biopsy-confirmed wild-type or variant ATTR-CM and NYHA class I-III symptoms took part in ATTR-ACT between 2013 and 2018. During the trial, the cause of hospitalisation was adjudicated by an independent committee. The hazard ratio (HR) for first CV-related hospitalisation was calculated using a Cox proportional hazards model. The HR for recurrent CV-related hospitalisation was calculated using the Liu-Wei-Yang-Ying (LWYY; also known as the modified Anderson-Gill) model. Models compared tafamidis meglumine 80 mg vs placebo and adjusted for transthyretin genotype (wild-type or variant). In the overall population, the LWYY model was also adjusted for baseline NYHA class. Results The frequency of adjudicated CV-related hospitalisations during ATTR-ACT by NYHA class are shown in the Figure. Across patients who were NYHA class I-III at baseline, the risk of recurrent CV-related hospitalisation was 37% lower in those who received tafamidis vs placebo treatment (HR 0.627 [95% CI 0.463, 0.848]; P=0.0025; Table). Among those who were NYHA class I/II at baseline, a lower proportion of tafamidis- vs placebo-treated patients (44% vs 61%) had ≥1 CV-related hospitalisation. The risks of first and recurrent CV-related hospitalisation were 40% (HR 0.601 [95% CI 0.420, 0.861]; P=0.0055) and 55% (HR 0.449 [95% CI 0.305, 0.661]; P&lt;0.0001) lower with tafamidis vs placebo treatment. Consistent with the survivor bias previously observed in ATTR-ACT,(1-4) the risk of recurrent CV-related hospitalisation was statistically similar in tafamidis- and placebo-treated patients who were NYHA class III at baseline (HR 1.113 [95% CI 0.688, 1.799]; P=0.6624). Conclusions Building on previous findings, this analysis found the risk of recurrent CV-related hospitalisation to be reduced by tafamidis meglumine 80 mg treatment in patients with early stage ATTR-CM.